74 related articles for article (PubMed ID: 2370643)
1. The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol.
Elliott HL; Macphee GJ; Meredith PA
J Hum Hypertens; 1990 Jun; 4 Suppl 2():45-8. PubMed ID: 2370643
[TBL] [Abstract][Full Text] [Related]
2. The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol.
Macphee GJ; Howie CA; Meredith PA; Elliott HL
Br J Clin Pharmacol; 1991 Nov; 32(5):591-7. PubMed ID: 1954075
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological evaluation of dilevalol vasodilating properties in mild to moderate hypertension.
Drici MD; Candito M; Ferrari E; Jacomet Y; Morand P; Lapalus P
Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):361-5. PubMed ID: 1937998
[TBL] [Abstract][Full Text] [Related]
4. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
Lalonde RL; Tenero DM; Kazierad DJ
Pharmacotherapy; 1990; 10(1):15-28. PubMed ID: 2179899
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study.
Soberman J; Greenberg S; Frishman W
J Clin Hypertens; 1987 Sep; 3(3):271-7. PubMed ID: 3312501
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy and safety of dilevalol in the treatment of essential arterial hypertension].
Bochicchio T; Pérez-Grovas HA; Carrizosa J; Herrera-Acosta J
Arch Inst Cardiol Mex; 1989; 59(2):181-6. PubMed ID: 2569857
[TBL] [Abstract][Full Text] [Related]
7. Effects of dilevalol and propranolol on hemodynamics in patients with essential hypertension.
Hama J; Oda A; Hirano Y; Horiuchi M; Katori R
Clin Ther; 1991; 13(4):467-70. PubMed ID: 1933998
[TBL] [Abstract][Full Text] [Related]
8. Overview of clinical trials of dilevalol in essential hypertension.
Glover DR; Tarbit WJ
J Hum Hypertens; 1990 Jun; 4 Suppl 2():49-53. PubMed ID: 2142508
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses.
Rocci ML; Vlasses PH; Cressman MD; Sirgo MA; Plachetka JR
Pharmacotherapy; 1990; 10(2):92-9. PubMed ID: 2349138
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly R; Macphee GJ
Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
[TBL] [Abstract][Full Text] [Related]
11. Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension.
Tham TC; Silke B; Taylor SH
J Hum Hypertens; 1990 Jun; 4 Suppl 2():77-83. PubMed ID: 2370647
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of dilevalol in renal impairment.
Kelly JG; Laher MS; Donohue J; Doyle GD
J Hum Hypertens; 1990 Jun; 4 Suppl 2():59-62. PubMed ID: 2370645
[TBL] [Abstract][Full Text] [Related]
13. Intravenous dilevalol in the treatment of severe hypertension.
Bursztyn M; Gavras I; Blasucci DJ; Gavras H
J Cardiovasc Pharmacol; 1989 May; 13(5):799-802. PubMed ID: 2472530
[TBL] [Abstract][Full Text] [Related]
14. Dilevalol in severe hypertension. A multicenter trial of bolus intravenous dosing.
Wallin JD; Cook ME; Fletcher E; Holtzman JL; Winer N; Gavras H; Grim CE; Ramanathan KB; Vidt DG; Johnson BF
Arch Intern Med; 1989 Dec; 149(12):2655-61. PubMed ID: 2688585
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
Rasmussen S; Nielsen PE
Postgrad Med J; 1980; 56 Suppl 2():33-6. PubMed ID: 7433340
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.
Given BD; Perentesis G; Christopher JD; Herron J; Patrick JE; Kramer WG; Affrime MB
Am J Cardiol; 1989 Jun; 63(19):12I-16I. PubMed ID: 2729123
[TBL] [Abstract][Full Text] [Related]
18. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
[TBL] [Abstract][Full Text] [Related]
19. Use of moxonidine in elderly patients with resistant hypertension.
Martin U; Hill C; O' Mahony D
J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
[TBL] [Abstract][Full Text] [Related]
20. Changes in lymphocyte beta-adrenoceptor density after dilevalol oral treatment.
Sbirrazzuoli V; Drici M; Garraffo R; Candito M; Gibelin P; Morand P; Lapalus P
Drugs Exp Clin Res; 1989; 15(5):223-9. PubMed ID: 2551622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
